Modular Medical (Nasdaq:MODD) has shared new data highlighting the use of its insulin pump technology to deliver GLP-1 therapeutics.
The company shared its findings in a poster presentation at the American Diabetes Association’s 85th Scientific Sessions in Chicago.
San Diego-based Modular Medical develops the MODD1 product, a 90-day patch pump. It features new microfluidics technology to allow for the low-cost pumping of insulin. Its new intuitive design makes the product simple to use and easier to prescribe. MODD1 earned FDA clearance for MODD1 in September 2024. The company also raised $12 million this year.
The company utilized its technology in a study evaluating a pump-delivered subcutaneous GLP-1R agonist in a diet-induced obese mouse model.
According to the company’s poster, GLP-1R agonist therapies can manifest significant gastrointestinal side effects. To combat this, the company believes that a subcutaneous pump could establish the locus of treatment control for the patient.
Related: Tandem’s t:slim X2 pump now works with Abbott’s FreeStyle CGM sensor
In the Modular Medical study, the therapy elicited weight-lowering effects in the DIO mouse model, whether administered by intermittent subcutaneous injection or subcutaneous pump. Semaglutide exhibited the more potent weight-lowering effect compared to exenatide.
Modular Medical concluded that study results suggest that basal-bolus pump GLP-1RA delivery can recapitulate the therapy’s weight-lowering effects observed with intermittent dosing. Additional food intake and oral glucose tolerance challenge data also suggest potential differentiated attributes when comparing pump delivery to standard intermittent dosing.
While the mouse model differs from the clinic, the company said its findings support further investigation of pump-delivered GLP-1RA therapy in individuals with type 2 diabetes.
“Given the high rate of gastrointestinal tolerability challenges and resultant discontinuation that is characteristic of GLP-1 therapy, we believe that a personalized approach to GLP-1 titration and dosing, including a mealtime bolus option, would give patients an opportunity to reach their treatment goals, while experiencing easier therapy initiation and a more tolerable maintenance regimen,” said Jeb Besser, CEO of Modular Medical.
